February 18, 2019

Login to your account

Username *
Password *
Remember Me

Create an account

Fields marked with an asterisk (*) are required.
Name *
Username *
Password *
Verify password *
Email *
Verify email *
Captcha *
Reload Captcha

Miracle CURE for sight loss: Patients regain eyesight after breakthrough macular treatment

20.3.2018 By MARK REYNOLDS   https://www.express.co.uk/

SCIENTISTS yesterday hailed a major breakthrough in treating the most common form of sight loss after two patients miraculously regained their vision.

Douglas Waters, 86, and an unnamed woman in her early 60s were suffering from age-related macular degeneration.

It is a condition that leads to a rapid loss of central vision and affects more than 600,000 people in Britain.

But after undergoing the ground-breaking clinical trial - where each received a new stem cell-based treatment during an hour-long operation - they were amazed by the staggering results.

Mr Waters, from Croydon, south London, who developed the condition in his right eye three years ago, said: "In the months before the operation my sight was really poor and I couldn't see anything out of my right eye. I was struggling to see things clearly, even when up close.

"After the surgery my eyesight improved to the point where I can now read the newspaper and help my wife out with the gardening.

"It's brilliant what the team has done and I feel so lucky to have been given my sight back."

The treatment saw cells from a human embryo grown into a patch in a laboratory before being delicately inserted into the back of the eye.

Last night, the scientists behind the treatment, which they compared to "laying a new carpet", said they hoped the breakthrough could lead to an "off-theshelf" treatment within five years.

Professor Lyndon da Cruz, consultant ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust in London, said: "We've restored vision where there was none.

"It's incredibly exciting. As you get older, parts of you stop working and for the first time we've been able to take a cell and make it into a specific part of the eye that's failing and put it in the eye and get vision back."

The results suggest that this new therapeutic approach is safe and provides good visual outcomes.
Professor Lyndon da Cruz

He added: "The results suggest that this new therapeutic approach is safe and provides good visual outcomes. The patients who received the treatment had very severe AMD, and their improved vision will go some way to enhancing their quality of life.

"We recognise that this is a small group of patients, but we hope that what we have learned from this study will benefit many more in the future."

Age-related macular degeneration is the leading cause of blindness in the UK and the third globally.

Both patients in the trial had "wet" age-related macular degeneration.

This form of the disease is caused by abnormal blood vessels growing through the retinal pigment epithelium and damaging the macula.

Dry age-related macular degeneration is more common and caused by the retinal pigment epithelium breaking down. It is hoped the patch will be able to treat both forms.

Professor Pete Coffey, from the UCL Institute of Ophthalmology, said: "This study represents real progress in regenerative medicine and opens the door on new treatment options for people with age-related macular degeneration."

The treatment marked the first time an engineered piece of tissue has been successfully used to treat people with sudden severe sight loss.

It saw researchers investigating whether the diseased cells at the back of the patients' affected eyes could be replenished using a stem cell patch.

A specially engineered surgical tool was then used to insert the patch under the retina in the eye of each patient in an operation lasting between one to two hours.

It is hoped the length of this procedure will be shortened to around 45 minutes.

The patients - who went from not being able to read at all, even with glasses, to reading 60 to 80 words per minute with normal reading glasses - were monitored for 12 months before reporting major improvements in their vision.

The successful clinical trial was the result of a partnership between Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology and the National Institute for Health Research.

The findings of the trial are published in the journal Nature Biotechnology. 



Rate this item
(0 votes)
Last modified on Sunday, 01 April 2018 19:00

Leave a comment

Make sure you enter all the required information, indicated by an asterisk (*). HTML code is not allowed.

Latest Tweets

@SeketricBarnes They run the "world" since they installed priests and kings to rule over the "sheep" = food They ca… https://t.co/9wnW41vHeg
RT @RalfTHeuer: Königin ist für schuldig befunden,… ...ist unwiderlegbar bewiesen bezüglich.. Elizabeth II, daß die Königin bereits nach 3.…
RT @leibundgutmanu1: Südkorea: Tausende Pillen mit pulverisiertem, menschlichem Babyfleisch von Zollbeamten entdeckt https://t.co/LH8g8b2oRA
RT @JohnnyG49343439: @OrwellNGoode https://t.co/tiZg55QXRe
RT @HeshmatAlavi: Watch how #Iran's state media resorts to using children (who obviously don't know what they're saying) to spread their fi…
Follow Ana Litika on Twitter

Post Gallery

Report: Hamas Using Facebook To Coordinate Attacks on Gaza Strip

Alle chilenischen Bischöfe treten nach Missbrauchsskandal zurück

The secret backstory of how Obama let Hezbollah off the hook

Apple co-founder Steve Wozniak laments the current deceit of big tech

Trump Admin. Blocked Toxic Chemicals Study Fearing 'Public Relations Nightmare'

IG Report on Clinton Investigation “extremely long and thorough”

Search warrant for Weiner’s electronic devices unsealed

Masters of the Universe: Leaked Video Shows Google’s Vision of ‘Total Data Collection’

BUCKLE UP: DOJ Inspector FINISHES REPORT on Hillary Email Scandal

© 2018 Namluu All Rights Reserved.